Canada Pension Plan Investment Board Sells 36,000 Shares of Amedisys, Inc. (NASDAQ:AMED)

Canada Pension Plan Investment Board cut its position in shares of Amedisys, Inc. (NASDAQ:AMED - Free Report) by 35.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 66,000 shares of the health services provider's stock after selling 36,000 shares during the quarter. Canada Pension Plan Investment Board owned about 0.20% of Amedisys worth $5,992,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in AMED. Norges Bank purchased a new stake in shares of Amedisys in the 4th quarter worth approximately $83,061,000. Wealthfront Advisers LLC purchased a new stake in shares of Amedisys in the fourth quarter worth $72,970,000. Pacer Advisors Inc. increased its holdings in shares of Amedisys by 11,621.9% during the fourth quarter. Pacer Advisors Inc. now owns 558,197 shares of the health services provider's stock valued at $50,679,000 after acquiring an additional 553,435 shares in the last quarter. Birnam Oak Advisors LP purchased a new position in shares of Amedisys in the 4th quarter worth about $15,832,000. Finally, Calamos Advisors LLC boosted its stake in Amedisys by 22.7% in the 4th quarter. Calamos Advisors LLC now owns 487,444 shares of the health services provider's stock worth $44,255,000 after purchasing an additional 90,097 shares in the last quarter. 94.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $100.00 target price on shares of Amedisys in a report on Wednesday, April 16th. Stephens restated an "equal weight" rating and issued a $101.00 price target on shares of Amedisys in a research note on Tuesday, March 4th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $100.75.

Amedisys Stock Performance

NASDAQ:AMED traded up $0.23 during trading hours on Friday, reaching $94.50. The company had a trading volume of 361,426 shares, compared to its average volume of 406,625. The firm has a market cap of $3.10 billion, a price-to-earnings ratio of 37.50, a PEG ratio of 1.78 and a beta of 0.89. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05. The firm's 50 day moving average price is $92.21 and its 200-day moving average price is $91.75. Amedisys, Inc. has a 52 week low of $82.15 and a 52 week high of $98.95.

Amedisys (NASDAQ:AMED - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The health services provider reported $1.25 EPS for the quarter, beating analysts' consensus estimates of $1.13 by $0.12. The company had revenue of $594.78 million during the quarter, compared to analysts' expectations of $597.43 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. On average, analysts forecast that Amedisys, Inc. will post 4.4 EPS for the current year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.